Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.

AIM Two unexplored aspects for irinotecan and cisplatin (I&C) combination chemotherapy are: actively targeting both drugs to a specific diseased cell type, and delivering both drugs on the same vehicle to ensure their synchronized entry into the cell at a well-defined ratio. In this work, the authors report the use of targeted polymeric nanoparticles (NPs) to coencapsulate and deliver I&C to cancer cells expressing the prostate-specific membrane antigen. MATERIALS & METHODS Targeted NPs were prepared in a single step by mixing four different precursors inside microfluidic devices. RESULTS I&C were encapsulated in 55-nm NPs and showed an eightfold increase in internalization by prostate-specific membrane antigen-expressing LNCaP cells compared with nontargeted NPs. NPs coencapsulating both drugs exhibited strong synergism in LNCaP cells with a combination index of 0.2. CONCLUSION The strategy of coencapsulating both I&C in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer.

[1]  A. Kozikowski,et al.  A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. , 2009, Journal of medicinal chemistry.

[2]  N. Hanna,et al.  Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Mayer,et al.  Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo , 2009, Molecular Cancer Therapeutics.

[4]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.

[5]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[6]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[7]  Omid C Farokhzad,et al.  Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. , 2011, Accounts of chemical research.

[8]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[9]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[10]  Liangfang Zhang,et al.  Nanoparticle-assisted combination therapies for effective cancer treatment. , 2010, Therapeutic delivery.

[11]  P. Low,et al.  Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. , 2009, Molecular pharmaceutics.

[12]  Martin G Pomper,et al.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. , 2009, Cancer research.

[13]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[14]  Robert Langer,et al.  Synthesis of Size‐Tunable Polymeric Nanoparticles Enabled by 3D Hydrodynamic Flow Focusing in Single‐Layer Microchannels , 2011, Advanced materials.

[15]  Robert Langer,et al.  Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. , 2010, ACS nano.

[16]  Robert Langer,et al.  Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.

[17]  M. D. Blanco,et al.  Targeted Nanoparticles for Cancer Therapy , 2012 .

[18]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[19]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[20]  P. Low,et al.  Ligand‐Targeted Delivery of Small Interfering RNAs to Malignant Cells and Tissues , 2009, Annals of the New York Academy of Sciences.

[21]  Christine Vauthier,et al.  Measurement of the Density of Polymeric Nanoparticulate Drug Carriers by Isopycnic Centrifugation , 1999 .

[22]  Martin G. Pomper,et al.  Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA) , 2008, Cancer biology & therapy.

[23]  M. Bally,et al.  Irinotecan–cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line , 2007, Cancer Chemotherapy and Pharmacology.

[24]  Robert K Prud'homme,et al.  Mechanism for rapid self-assembly of block copolymer nanoparticles. , 2003, Physical review letters.

[25]  Robert Langer,et al.  Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. , 2011, Biomaterials.

[26]  D. Prager,et al.  A phase II trial of irinotecan in hormone-refractory prostate cancer , 1998, Investigational New Drugs.

[27]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[28]  Robert Langer,et al.  Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. , 2007, Biomaterials.

[29]  K. Avgoustakis,et al.  Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. , 2004, Current drug delivery.

[30]  Robert Langer,et al.  Microfluidic platform for controlled synthesis of polymeric nanoparticles. , 2008, Nano letters.

[31]  J. Supko,et al.  Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  Pedro M. Valencia,et al.  Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation , 2012 .

[33]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[34]  Stephen J Lippard,et al.  Direct cellular responses to platinum-induced DNA damage. , 2007, Chemical reviews.

[35]  M. Bally,et al.  Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.